Page last updated: 2024-12-08

dithioerythritol

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID439352
CHEMBL ID1232391
CHEBI ID17456
SCHEMBL ID78921
MeSH IDM0006614

Synonyms (51)

Synonym
CHEMBL1232391
2,3-dihydroxy-1,4-dithiolbutane
dithioerythreitol
1,4-dithioerythritol
(2r,3s)-1,4-disulfanylbutane-2,3-diol
CHEBI:17456 ,
(2r*,3s*)-1,4-dimercapto-2,3-butanediol
brn 1719756
2,3-butanediol, 1,4-dimercapto-, (theta,s)-
einecs 229-998-8
(r*,s*)-1,4-dimercaptobutane-2,3-diol
2,3-butanediol, 1,4-dimercapto-, (2r,3s)-rel-
(r*,s*)-1,4-dimercapto-2,3-butanediol
erythritol, 1,4-dithio-
2,3-butanediol, 1,4-dimercapto-, (r*,s*)-
DTU ,
(2r,3s)-1,4-dimercaptobutane-2,3-diol
dte ,
6892-68-8
dithioerythritol ,
C00950
erythro-1,4-dimercapto-2,3-butanediol
1,4-dithioerythritol, bioxtra, >=99.0%
1,4-dithioerythritol, bioreagent, for molecular biology, >=99.0%
1,4-dithioerythritol, >=99.0%
DB01692
1,4-dithioerythritol, bioultra, >=99.0% (rt)
(2r,3s)-1,4-bis(sulfanyl)butane-2,3-diol
D1320
2,3-dihydroxy-1,4-butanedithiol
(2r,3s)-1,4-bis(sulfanyl)butane-2,3-diol;dte
A836288
unii-r4svl81gqi
r4svl81gqi ,
3-01-00-02359 (beilstein handbook reference)
(2s,3r)-1,4-bis(sulfanyl)butane-2,3-diol
cleland inverted exclamation mark s reagent
AKOS015902817
HY-15916
SCHEMBL78921
VHJLVAABSRFDPM-ZXZARUISSA-N
trans-1,4-dimercaptobutane-2,3-diol
mfcd00063750
(2r*,3s*)-1,4-dimercaptobutane-2,3-diol
1,4-dithioerythritol, >=99.0% (rt)
1,4-dithioerythritol, 99%
erythro-1,4,-dimercapto-2,3-butanediol
Q412701
FS-4113
D89833
DTXSID40884341

Research Excerpts

Toxicity

ExcerptReferenceRelevance
"The rationale for melanoma specific dihydroxybenzene containing antitumor agents is based in part upon the ability of the enzyme tyrosinase to oxidize these pro drugs to toxic intermediates."( Effects of tyrosinase activity on the cytotoxicity of 3,4-dihydroxybenzylamine and buthionine sulfoximine in human melanoma cells.
Fitzgerald, GB; Prezioso, JA; Wick, MM,
)
0.13
" Salvianic acid A (SA), isolated from the Chinese herbal medicine Salvia miltiorrhiza, is capable of protecting diverse kinds of cells from damage caused by a variety of toxic stimuli."( Salvianic acid A protects human neuroblastoma SH-SY5Y cells against MPP+-induced cytotoxicity.
Wang, XJ; Xu, JX, 2005
)
0.33

Pharmacokinetics

ExcerptReferenceRelevance
" Furthermore, BH(4) and total biopterin were measured at different time intervals (up to 33 h after oral administration) and pharmacokinetic parameters T(max) (1-4h), C(max) (258."( Plasma tetrahydrobiopterin and its pharmacokinetic following oral administration.
Ballhausen, D; Blau, N; Fiege, B; Goriounov, D; Kierat, L; Leimbacher, W; Schircks, B; Thöny, B, 2004
)
0.32

Dosage Studied

ExcerptRelevanceReference
" Co-incubation with DTE (n=3) resulted in dose-response prevention of the inhibitory effects of 100 microM deleterious TPT concentrations on 17beta-HSD 3 (EC(50) value of 12."( Dithioerythritol (DTE) prevents inhibitory effects of triphenyltin (TPT) on the key enzymes of the human sex steroid hormone metabolism.
Albers, P; Alléra, A; Heimbrecht, J; Jantzen, E; Klingmüller, D; Lo, S; Steckelbroeck, S, 2003
)
1.76
"0 nmol/L biopterin at a dosage of 10mg/kg), and area under the curve (AUC=1708-1958 nmol(*)h/L up to T=10h) were estimated."( Plasma tetrahydrobiopterin and its pharmacokinetic following oral administration.
Ballhausen, D; Blau, N; Fiege, B; Goriounov, D; Kierat, L; Leimbacher, W; Schircks, B; Thöny, B, 2004
)
0.32
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (1)

RoleDescription
reducing agentThe element or compound in a reduction-oxidation (redox) reaction that donates an electron to another species.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (1)

ClassDescription
1,4-dimercaptobutane-2,3-diolA glycol that is butane-2,3-diol in which a hydrogen from each of the methyl groups is replaced by a thiol group.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (10)

PathwayProteinsCompounds
superpathway of hydrolyzable tannin biosynthesis023
alkane biosynthesis II116
pentagalloylglucose biosynthesis012
3-hydroxypropanoate/4-hydroxybutanate cycle1840
t-anethole biosynthesis215
alkane biosynthesis II114
penicillin G and penicillin V biosynthesis319
glyoxylate assimilation1131
superpathway of hydrolyzable tannin biosynthesis030
glycerol degradation II318
superpathway of glycerol degradation to 1,3-propanediol826
epoxypseudoisoeugenol-2-methylbutanoate biosynthesis222

Bioassays (1)

Assay IDTitleYearJournalArticle
AID1128913Inhibition of metallo-beta-lactamase IMP-1 (unknown origin)2014European journal of medicinal chemistry, Apr-09, Volume: 76The applications of binuclear metallohydrolases in medicine: recent advances in the design and development of novel drug leads for purple acid phosphatases, metallo-β-lactamases and arginases.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (274)

TimeframeStudies, This Drug (%)All Drugs %
pre-1990159 (58.03)18.7374
1990's52 (18.98)18.2507
2000's32 (11.68)29.6817
2010's30 (10.95)24.3611
2020's1 (0.36)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 31.98

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index31.98 (24.57)
Research Supply Index5.67 (2.92)
Research Growth Index4.25 (4.65)
Search Engine Demand Index44.07 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (31.98)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials2 (0.69%)5.53%
Reviews2 (0.69%)6.00%
Case Studies1 (0.35%)4.05%
Observational0 (0.00%)0.25%
Other283 (98.26%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]